NCT00781612: A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies

NCT00781612
Breast Cancer Type: HER2+
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Therapeutic Antibody, Chemotherapy, Immunotherapy

Key Eligibility Criteria:

Gender: All
Age: Child, Adult, Older Adult
Location of Metastases: 
Additional Notes: 
Exclusions: Patients who have not been treated with single-agent or combination Kadcyla/trastuzumab emtansine (T-DM1)
https://ClinicalTrials.gov/show/NCT00781612

Comments are closed.

Up ↑